labcorp Testing will be performed at a Labcorp laboratory, including formerly branded Dianon Pathology.

generally do not cover routine screening tests. # = Medicare deems investigational. Medicare does not pay for services it deems investigational. Refer to Determining Necessity of ABN Completion on Reverse

SPECIMEN LABEL INSTRUCTIONS:
1.) Complete the requisition with all requested information.
2.) Remove the required number of labels from the front of this sheet.
3.) Place one (1) label on each specimen

container (not on the lid).

PLEASE DISPOSE OF UNUSED LABELS.

Dianon Systems, Inc. 2440 S Sepulveda Blvd, Ste 181 Los Angeles, CA 90064 T: (800) 352-7788, Ext 4126 F: (888) 727-8378 dianon.labcorp.com

CLIENT INFORMATION				DILLING INFORMA	TION (lace sheet & front	and back of insurance ca	rd must be attached)
REQUESTING		NPI#			isurance 🗆 Medicare		atient 🛛 Workers Co
PHYSICIAN REFERRING		NPI#		Patient Status: 🗆 Hospita			Hospital Patient
PHYSICIAN		141 1//					
					See attached		
				Insured Information: Name	9		
				Relationship to Patient (circle of	one) Self Spouse C	hild Other:	
				Primary Insurance Co:		Authorization	ı #
				Billing Address		Insured #	
				Billing City, State, Zip		Group #	
			Secondary Insurance Co:	Authorization #			
				Billing Address		Insured #	
PATIENT INFORMATION				Billing City, State, Zip		Group #	
lame (last, first, middle)					ATION		
Address				Collection Date: MM /		Time:	□ A.M. □ P.M.
				Number of Jars:			L
City, State, Zip							
Date of Birth: MM / DD / YYY	Y	Sex 🗆 M	□ F	All diagnoses should be provi Diagnosis/Signs/Symptoms in	5 01 5		0
Phone Number	Race:			REQUIRED		ICD-CM	
/rn / patient id #	Chart #			REQUIRED		100-01	
	Unart #			ICD-CM	ICD-CM	ICD-CM	
] H&E Histology† (Gross & Microscopic)] (D9F-1) Direct Immunofluorescence (IgA, Ig	G, IgM, C3) (Michel's I	Media) (88346, 88350	x 3)	Consultation <i>†</i> : On referred s	terial requiring slide prep (s	end pathology report) 8	
HISTOLOGY † Separately billable st H&E Histology † (Gross & Microscopic) (D9F-1) Direct Immunofluorescence (IgA, Ig (D9H-1) Direct Immunofluorescence, (Fibrinoge BRAF Gene Mutation Analysis, Melanoma (4)	G, IgM, C3) (Michel's I n, IgA, IgG, IgM, C3) (Mi	Media) (88346, 88350 ichel's Media) (88346, 88	x 3)	Consultation <i>†</i> : On referred s	terial requiring slide prep (s	end pathology report) 8	
H&E Histology† (Gross & Microscopic) (D9F-1) Direct Immunofluorescence (IgA, Ig (D9H-1) Direct Immunofluorescence, (Fibrinoge	G, IgM, C3) (Michel's I n, IgA, IgG, IgM, C3) (Mi 81110)(send pathology	Media) (88346, 88350 i chel's Media) (88346, 88 r report) 81210, 88381 d apply appropriate	x 3) 8350 x 4) <i>label to jar)</i>	Consultation <i>†</i> : On referred s	terial requiring slide prep (s	end pathology report) 8	
H&E Histology / (Gross & Microscopic) (D9F-1) Direct Immunofluorescence (IgA, Ig (D9H-1) Direct Immunofluorescence, (Fibrinoge BRAF Gene Mutation Analysis, Melanoma (4 BIOPSY DATA (please identify anal	G, IgM, C3) (Michel's I n, IgA, IgG, IgM, C3) (Mi 81110)(send pathology tomic site below and	Media) (88346, 88350 ichel's Media) (88346, 88 r report) 81210, 88381 d apply appropriate Specimen	x 3) 8350 x 4) label to jar) Type	Consultation <i>†</i> : On referred s	terial requiring slide prep (s	end pathology report) 8	Signs & Symptom
H&E Histology / (Gross & Microscopic) (D9F-1) Direct Immunofluorescence (IgA, Ig (D9H-1) Direct Immunofluorescence, (Fibrinoge BRAF Gene Mutation Analysis, Melanoma (4 BIOPSY DATA (please identify analysis) Jar # Body Site/Descr	G, IgM, C3) (Michel's I n, IgA, IgG, IgM, C3) (Mi 81110)(send pathology tomic site below and	Media) (88346, 88350 i chel's Media) (88346, 88 r report) 81210, 88381 d apply appropriate	x 3) 8350 x 4) label to jar) Type	Consultation <i>†</i> : On referred s	terial requiring slide prep (s	end pathology report) 8	Signs & Symptom
H&E Histology / (Gross & Microscopic) (D9F-1) Direct Immunofluorescence (IgA, Ig (D9H-1) Direct Immunofluorescence, (Fibrinoge BRAF Gene Mutation Analysis, Melanoma (4 BIOPSY DATA (please identify anal) Jar # Body Site/Descr 1	G, IgM, C3) (Michel's I n, IgA, IgG, IgM, C3) (Mi 81110)(send pathology tomic site below and	Media) (88346, 88350 ichel's Media) (88346, 88 r report) 81210, 88381 d apply appropriate Specimen	x 3) 8350 x 4) label to jar) Type	Consultation <i>†</i> : On referred s	terial requiring slide prep (s	end pathology report) 8	Signs & Symptom
H&E Histology / (Gross & Microscopic) (D9F-1) Direct Immunofluorescence (IgA, Ig (D9H-1) Direct Immunofluorescence, (Fibrinoge BRAF Gene Mutation Analysis, Melanoma (4 BIOPSY DATA (please identify analysis) Jar # Body Site/Descr	G, IgM, C3) (Michel's I n, IgA, IgG, IgM, C3) (Mi 81110)(send pathology tomic site below and	Media) (88346, 88350 ichel's Media) (88346, 88 r report) 81210, 88381 d apply appropriate Specimen	x 3) 8350 x 4) label to jar) Type	Consultation <i>†</i> : On referred s	terial requiring slide prep (s	end pathology report) 8	Signs & Symptom
H&E Histology / (Gross & Microscopic) (D9F-1) Direct Immunofluorescence (IgA, Ig (D9H-1) Direct Immunofluorescence, (Fibrinoge BRAF Gene Mutation Analysis, Melanoma (4 BIOPSY DATA (please identify anal) Jar # Body Site/Descr 1	G, IgM, C3) (Michel's I n, IgA, IgG, IgM, C3) (Mi 81110)(send pathology tomic site below and	Media) (88346, 88350 ichel's Media) (88346, 88 r report) 81210, 88381 d apply appropriate Specimen	x 3) 8350 x 4) label to jar) Type	Consultation <i>†</i> : On referred s	terial requiring slide prep (s	end pathology report) 8	Signs & Symptom
H&E Histology / (Gross & Microscopic) (D9F-1) Direct Immunofluorescence (IgA, Ig (D9H-1) Direct Immunofluorescence, (Fibrinoge BRAF Gene Mutation Analysis, Melanoma (4 BIOPSY DATA (please identify anal) Jar # Body Site/Descr 1 2	G, IgM, C3) (Michel's I n, IgA, IgG, IgM, C3) (Mi 81110)(send pathology tomic site below and	Media) (88346, 88350 ichel's Media) (88346, 88 r report) 81210, 88381 d apply appropriate Specimen	x 3) 8350 x 4) label to jar) Type	Consultation <i>†</i> : On referred s	terial requiring slide prep (s	end pathology report) 8	
H&E Histology / (Gross & Microscopic) (D9F-1) Direct Immunofluorescence (IgA, Ig (D9H-1) Direct Immunofluorescence, (Fibrinoge BRAF Gene Mutation Analysis, Melanoma (4 BIOPSY DATA (please identify analysis) Jar # Body Site/Descr 1 2 3	G, IgM, C3) (Michel's I n, IgA, IgG, IgM, C3) (Mi 81110)(send pathology tomic site below and	Media) (88346, 88350 ichel's Media) (88346, 88 r report) 81210, 88381 d apply appropriate Specimen	x 3) 8350 x 4) label to jar) Type	Consultation <i>†</i> : On referred s	terial requiring slide prep (s	end pathology report) 8	Signs & Symptom
H&E Histology / (Gross & Microscopic) (D9F-1) Direct Immunofluorescence (IgA, Ig (D9H-1) Direct Immunofluorescence, (Fibrinoge BRAF Gene Mutation Analysis, Melanoma (4 BIOPSY DATA (please identify anal Jar # Body Site/Descr 1 2 3 4 5	G, IgM, C3) (Michel's I n, IgA, IgG, IgM, C3) (Mi 81110)(send pathology tomic site below and	Media) (88346, 88350 ichel's Media) (88346, 88 r report) 81210, 88381 d apply appropriate Specimen	x 3) 8350 x 4) label to jar) Type	Consultation <i>†</i> : On referred s	terial requiring slide prep (s	end pathology report) 8	Signs & Symptom
H&E Histology / (Gross & Microscopic) (D9F-1) Direct Immunofluorescence (IgA, Ig (D9H-1) Direct Immunofluorescence, (Fibrinoge BRAF Gene Mutation Analysis, Melanoma (4 BIOPSY DATA (please identify analysis) Jar # Body Site/Descr 1 2 3 4	G, IgM, C3) (Michel's I n, IgA, IgG, IgM, C3) (Mi 81110)(send pathology tomic site below and riptor	Media) (88346, 88350 ichel's Media) (88346, 86 v report) 81210, 88381 d apply appropriate Specimen (biopsy, exc	x 3) 8350 x 4) Iabel to jar) Type cision)	Consultation # : On referred a	terial requiring slide prep (s	end pathology report) 8	Signs & Sympton
H&E Histology / (Gross & Microscopic) (D9F-1) Direct Immunofluorescence (IgA, Ig (D9H-1) Direct Immunofluorescence, (Fibrinoge BRAF Gene Mutation Analysis, Melanoma (4 BIOPSY DATA (please identify anal Jar # Body Site/Descr 1 2 3 4 5 6	G, IgM, C3) (Michel's I n, IgA, IgG, IgM, C3) (Mi 81110)(send pathology tomic site below and iptor	Media) (88346, 88350 ichel's Media) (88346, 86 v report) 81210, 88381 d apply appropriate Specimen (biopsy, exc	x 3) 8350 x 4) Iabel to jar) Type cision)	Consultation <i>†</i> : On referred to Consultation <i>†</i> : Referred the Consultation <i>†</i> : Referred the Consultation <i>†</i> : Referred the Comport of the Composite of	terial requiring slide prep (s	end pathology report) 8	Signs & Sympton
H&E Histology / (Gross & Microscopic) (D9F-1) Direct Immunofluorescence (IgA, Ig (D9H-1) Direct Immunofluorescence, (Fibrinoge BRAF Gene Mutation Analysis, Melanoma (4 BIOPSY DATA (please identify analysis) Jar # Body Site/Descr 1 1 2 3 3 4 5 6 6 Signs and Symptoms (DO NOT CIRCLE. W 1. Cyst 6. Plaqu 2. Keratosis 7. Scar	G, IgM, C3) (Michel's I n, IgA, IgG, IgM, C3) (Mi 81110)(send pathology tomic site below and iptor iptor	Media) (88346, 88350 ichel's Media) (88346, 88 r report) 81210, 88381 d apply appropriate Specimen (biopsy, exc biopsy, exc unber for each corres 11. Annular 12. Atrophy	x 3) 8350 x 4) Iabel to jar) Type cision) sponding specime 16. Gyrate/Se 17. Hair Loss	Consultation <i>f</i> : On referred a Consultation <i>f</i> : Referred ma Histology Technical Compor Histology Technical Compor	e.) 26. Telan istributed 27. Vesicl	giectasia 31. 0	Signs & Symptom (see below for cod
H&E Histology / (Gross & Microscopic) (D9F-1) Direct Immunofluorescence (IgA, Ig (D9H-1) Direct Immunofluorescence, (Fibrinoge BRAF Gene Mutation Analysis, Melanoma (4 BIOPSY DATA (please identify analysis) Jar # Body Site/Descr 1 1 2 3 3 4 5 6 6 Signs and Symptoms (DO NOT CIRCLE. W 1. Cyst 6. Plaqu 2. Keratosis 7. Scar 3. Nodule 8. Scar/	G, IgM, C3) (Michel's I n, IgA, IgG, IgM, C3) (Mi 81110)(send pathology tomic site below and iptor iptor 'riptor 'rite in applicable nu Je 'reexcision	Media) (88346, 88350 ichel's Media) (88346, 88 r report) 81210, 88381 d apply appropriate Specimen (biopsy, exc biopsy, exc unber for each corres 11. Annular 12. Atrophy 13. Bullae	x 3) 8350 x 4) Iabel to jar) Type cision) sponding specime 16. Gyrate/Se 17. Hair Loss 18. Hyperpigr	Consultation <i>f</i> : On referred a Consultation <i>f</i> : Referred ma Histology Technical Compor Histology Technical Compor	e.) 26. Telan istributed 27. Vesicl s 28. Ulcer	giectasia 31. 0	Signs & Symptom (see below for cod
H&E Histology / (Gross & Microscopic) (D9F-1) Direct Immunofluorescence (IgA, Ig (D9H-1) Direct Immunofluorescence, (Fibrinoge BRAF Gene Mutation Analysis, Melanoma (4 BIOPSY DATA (please identify analysis) Jar # Body Site/Descr 1 1 2 3 3 4 5 6 6 Signs and Symptoms (DO NOT CIRCLE. W 1. Cyst 6. Plaqu 2. Keratosis 7. Scar 3. Nodule 8. Scar/	G, IgM, C3) (Michel's I n, IgA, IgG, IgM, C3) (Mi 81110)(send pathology tomic site below and iptor iptor 'riptor 'rite in applicable nu Je 'reexcision	Media) (88346, 88350 ichel's Media) (88346, 88 r report) 81210, 88381 d apply appropriate Specimen (biopsy, exc biopsy, exc unber for each corres 11. Annular 12. Atrophy	x 3) 8350 x 4) Iabel to jar) Type cision) Sponding specime 16. Gyrate/Se 17. Hair Loss 18. Hyperpigr 19. Hypopign	Consultation <i>f</i> : On referred a Consultation <i>f</i> : Referred ma Histology Technical Compor Histology Technical Compor	e.) 26. Telan istributed 27. Vesicl a 29. Debrio	giectasia 31. 0	Signs & Symptom (see below for coor
H&E Histology / (Gross & Microscopic) (D9F-1) Direct Immunofluorescence (IgA, Ig (D9H-1) Direct Immunofluorescence, (Fibrinoge BRAF Gene Mutation Analysis, Melanoma (4 BIOPSY DATA (please identify analysis) Jar # Body Site/Descr 1 1 2 3 3 4 5 6 Signs and Symptoms (D0 NOT CIRCLE. W 1. Cyst 6. Plaqu 2. Keratosis 7. Scar 3. Nodule 8. Scar/4	G, IgM, C3) (Michel's I n, IgA, IgG, IgM, C3) (Mi 81110)(send pathology tomic site below and iptor iptor 'riptor 'rite in applicable nu Je 'reexcision	Media) (88346, 88350 ichel's Media) (88346, 88 report) 81210, 88381 d apply appropriate Specimen (biopsy, exc biopsy, exc 11. Annular 12. Atrophy 13. Bullae 14. Erythema 15. Excoriation	x 3) 8350 x 4) Iabel to jar) Type cision) Sponding specime 16. Gyrate/Se 17. Hair Loss 18. Hyperpigr 19. Hypopign	Consultation <i>f</i> : On referred a Consultation <i>f</i> : Referred ma Histology Technical Compor Histology Technical Compor en in the area provided above priginous 21. Pain Alopecia 22. Photodia mentation 23. Pruritus nentation 24. Purpura 25. Pustule	e.) 26. Telan istributed 27. Vesicl a 29. Debrio	giectasia 31. de	Signs & Sympton (see below for cod
H&E Histology / (Gross & Microscopic) (D9F-1) Direct Immunofluorescence (IgA, Ig (D9H-1) Direct Immunofluorescence, (Fibrinoge BRAF Gene Mutation Analysis, Melanoma (4 BIOPSY DATA (please identify analysis, Melanoma (4 Jar # Body Site/Descr 1 1 2 3 4 5 6 1 Signs and Symptoms (D0 NOT CIRCLE. W 1. Cyst 6. Plaqu 2. Keratosis 7. Scar 3. Nodule 8. Scar/ 4. Papule 9. Subc 5. Pigmented Neoplasm 10. Tag MICROBIOLOGY 008649	G, IgM, C3) (Michel's I n, IgA, IgG, IgM, C3) (Mi 81110)(send pathology tomic site below and iptor iptor irite in applicable nu Je freexcision utaneous Mass ure, General	Media) (88346, 88350 ichel's Media) (88346, 88 report) 81210, 88381 d apply appropriate (biopsy, exc biopsy, exc 11. Annular 12. Atrophy 13. Bullae 14. Erythema 15. Excoriation Ad CPT 87070	x 3) 8350 x 4) Iabel to jar) Type cision) Type cision) Sponding specime 16. Gyrate/Se 17. Hair Loss 18. Hyperpigr 19. Hypopigr 20. Macule	Consultation <i>f</i> : On referred a Consultation <i>f</i> : Referred ma Histology Technical Compor Histology Technical Compor en in the area provided above priginous 21. Pain Alopecia 22. Photodia mentation 23. Pruritus nentation 24. Purpura 25. Pustule	e.) 26. Telan istributed 27. Vesicl a 29. Debrio	giectasia 31. de	Signs & Sympton (see below for cod
H&E Histology / (Gross & Microscopic) (D9F-1) Direct Immunofluorescence (IgA, Ig (D9H-1) Direct Immunofluorescence, (Fibrinoge BRAF Gene Mutation Analysis, Melanoma (4 BIOPSY DATA (please identify analysis, Melanoma (4 Jar # Body Site/Descr 1 1 2 3 4 5 6 5 6 5 6 5 6 5 8. Nodule 8. Scar/ 9. Nodule 8. Scar/ 9. Papule 9. Subc 5. Pigmented Neoplasm 10. Tag MICROBIOLOGY 008649	G, IgM, C3) (Michel's I n, IgA, IgG, IgM, C3) (Mi 81110)(send pathology tomic site below and iptor iptor 'rite in applicable nu Je 'reexcision utaneous Mass ure, General ulture	Media) (88346, 88350 ichel's Media) (88346, 88 report) 81210, 88381 d apply appropriate Specimen (biopsy, exc biopsy, exc 11. Annular 12. Atrophy 13. Bullae 14. Erythema 15. Excoriation Ad	x 3) 8350 x 4) Iabel to jar) Type cision) Type cision) Sponding specime 16. Gyrate/Se 17. Hair Loss 18. Hyperpigr 19. Hypopigr 20. Macule	Consultation <i>f</i> : On referred a Consultation <i>f</i> : Referred ma Histology Technical Compor Histology Technical Compor en in the area provided above priginous 21. Pain Alopecia 22. Photodia mentation 23. Pruritus nentation 24. Purpura 25. Pustule	e.) 26. Telan istributed 27. Vesicl a 29. Debrio	giectasia 31. de	Signs & Symptor (see below for co
H&E Histology / (Gross & Microscopic) (D9F-1) Direct Immunofluorescence (IgA, Ig (D9H-1) Direct Immunofluorescence, (Fibrinoge BRAF Gene Mutation Analysis, Melanoma (4 BIOPSY DATA (please identify analysis, Melanoma (4 Jar # Body Site/Descr 1 1 2 3 3 4 5 6 Signs and Symptoms (D0 NOT CIRCLE. W 1. Cyst 6. Plaqu 2. Keratosis 7. Scar 3. Nodule 8. Scar/ 4. Papule 9. Subc 5. Pigmented Neoplasm 10. Tag MICROBIOLOGY 008649 Ou8649 Aerobic Bacterial Cult 008573 Viral Culture, General	G, IgM, C3) (Michel's I n, IgA, IgG, IgM, C3) (Mi 81110)(send pathology tomic site below and iptor iptor irite in applicable nu je reeexcision utaneous Mass ure, General ulture	Media) (88346, 88350 ichel's Media) (88346, 88 r report) 81210, 88381 d apply appropriate (biopsy, exc biopsy, exc 11. Annular 12. Atrophy 13. Bullae 14. Erythema 15. Excoriation Ad CPT 87070 CPT 87101 CPT 87252	x 3) 8350 x 4) Iabel to jar) Type cision) Type cision) Sponding specime 16. Gyrate/Se 17. Hair Loss 18. Hyperpigr 19. Hypopigr 20. Macule	Consultation <i>f</i> : On referred a Consultation <i>f</i> : Referred ma Histology Technical Compor Histology Technical Compor en in the area provided above priginous 21. Pain Alopecia 22. Photodia mentation 23. Pruritus nentation 24. Purpura 25. Pustule	e.) 26. Telan istributed 27. Vesicl a 29. Debrio	giectasia 31. de	Signs & Sympton (see below for cod
H&E Histology / (Gross & Microscopic) D9F-1) Direct Immunofluorescence (IgA, Ig (D9F-1) Direct Immunofluorescence, (Fibrinoge BRAF Gene Mutation Analysis, Melanoma (4 BIOPSY DATA (please identify analysis, Melanoma (4 BIOPSY DATA (please identify analysis, Melanoma (4 Jar # Body Site/Descr 1 1 2 2 3 4 5 6 Signs and Symptoms (D0 NOT CIRCLE. W 1. Cyst 6. Plaqu 2. Keratosis 7. Scar 3. Nodule 8. Scar/ 4. Papule 9. Subc 5. Pigmented Neoplasm 10. Tag MICROBIOLOGY 008649 008649 Aerobic Bacterial Cult 008573 Viral Culture, General 008573 Viral Culture, General 00ther:	G, IgM, C3) (Michel's I n, IgA, IgG, IgM, C3) (Mi 81110)(send pathology tomic site below and iptor iptor irite in applicable nu Je reeexcision utaneous Mass ure, General ulture arges per organisis adicaid reimbursement	Media) (88346, 88350 ichel's Media) (88346, 88 rreport) 81210, 88381 d apply appropriate Specimen (biopsy, exc 1. Annular 12. Atrophy 13. Bullae 14. Erythema 15. Excoriation CPT 87070 CPT 87101 CPT 87252 m if indicated. will be sought, physici	x 3) 8350 x 4) Iabel to jar) Type cision) Sponding specime 16. Gyrate/Se 17. Hair Loss 18. Hyperpigr 19. Hypopigm 20. Macule Iditional Clinical H	Consultation f : On referred a Consultation f : Referred ma Histology Technical Compor Histology Technical Compor en in the area provided above erpiginous 21. Pain Alopecia 22. Photodi mentation 23. Pruritus nentation 24. Purpura 25. Pustule istory:	e.) 26. Telan istributed 27. Vesicles 28. Ulcer a 29. Debrin 30. Soft T	end pathology report) 8 end pathology report) 8 giectasia 31. 0 le clement Tissue Mass treatment of the patient	Signs & Symptom (see below for cor
H&E Histology / (Gross & Microscopic) (D9F-1) Direct Immunofluorescence (IgA, Ig (D9H-1) Direct Immunofluorescence, (Fibrinoge BRAF Gene Mutation Analysis, Melanoma (4 BIOPSY DATA (please identify analysis, Melanoma (4 Jar # Body Site/Descr 1	G, IgM, C3) (Michel's I n, IgA, IgG, IgM, C3) (Mi 81110)(send pathology tomic site below and iptor iptor irite in applicable nu Je reeexcision utaneous Mass ure, General ulture arges per organisis adicaid reimbursement	Media) (88346, 88350 ichel's Media) (88346, 88 rreport) 81210, 88381 d apply appropriate Specimen (biopsy, exc 1. Annular 12. Atrophy 13. Bullae 14. Erythema 15. Excoriation CPT 87070 CPT 87101 CPT 87252 m if indicated. will be sought, physici	x 3) 8350 x 4) Iabel to jar) Type cision) Sponding specime 16. Gyrate/Se 17. Hair Loss 18. Hyperpigr 19. Hypopigm 20. Macule Iditional Clinical H	Consultation f : On referred a Consultation f : Referred ma Histology Technical Compor Histology Technical Compor en in the area provided above erpiginous 21. Pain Alopecia 22. Photodi mentation 23. Pruritus nentation 24. Purpura 25. Pustule istory:	e.) 26. Telan istributed 27. Vesiclis 29. Debrid 30. Soft T	end pathology report) 8 end pathology report) 8 giectasia 31. 0 le clement Tissue Mass treatment of the patient	Signs & Symptor (see below for co

8710117999

Test Combination/Panel Policy

Labcorp's policy is to provide physicians, in each instance, with the flexibility to choose appropriate tests to assure that the convenience of ordering test combinations/panels does not distance physicians who wish to order a test combination/profile from making deliberate decisions regarding which tests are truly medically necessary. All the tests offered in test combinations/panels may be ordered individually using the Labcorp request form. Labcorp encourages clients to contact their local Labcorp representative or Labcorp location if the testing configurations shown here do not meet individual needs for any reason, or if some other combination of procedures is desired.

In an effort to keep our clients fully informed of the content, charges and coding of its test combinations/panels when billed to Medicare, we periodically send notices concerning customized test combinations/panels, as well as information regarding patient fees for all Labcorp services. We also welcome the opportunity to provide, on request, additional information in connection with our testing services and the manner in which they are billed to physicians, health care plans, and patients.

The CPT code(s) listed are in accordance with the current edition of *Current Procedural Terminology*, a publication of the American Medical Association. CPT codes are provided for the convenience of our clients; however, correct coding often varies from one carrier to another. Consequently, the codes presented here are intended as general guidelines and should not be used without confirming with the applicable payor that their use is appropriate in each case. All laboratory procedures will be billed to third-party carriers (including Medicare and Medicaid) at fees billed to patients and in accordance with the specific CPT coding required by the carrier. Microbiology CPT code(s) for additional procedures such as susceptibility testing, identification, serotyping, etc. will be billed in addition to the primary codes when appropriate. Labcorp will process the specimen for a Microbiology test based on source.

Determining Necessity of Advance Beneficiary Notice of Non-coverage (ABN) Completion*

- 1. **Diagnose.** Determine your patient's diagnosis.
- 2. Document. Write the diagnosis code(s) on the front of this requisition.
- 3. Verify. Determine if the laboratory test(s) ordered for the patient is subject to Local Coverage Determination or National Coverage Determination. This information can be located in the policies published by your Medicare Administrative Contractor (MAC), CMS, or www.Labcorp.com/MedicareMedicalNecessity.
- 4. **Review.** If the diagnosis code for your patient <u>does not</u> meet the medical necessity requirements set forth by Medicare or the test(s) is being performed more frequently than Medicare allows, an ABN should be completed.

*An ABN should be completed for all tests that are considered investigational (experimental or for research use) by Medicare.

How to Complete an Advance Beneficiary Notice of Non-coverage (ABN)

Medicare is very specific in requiring that all of the information included on the ABN be completed. Additionally, Labcorp requests that the specimen number or bar code label be included on the form. To be valid an ABN must:

- 1. Be executed on the CMS approved ABN form (CMS-R-131)
- 2. Identify the Medicare Part B Beneficiary, using the name as it appears on the patient's red, white and blue Medicare card
- 3. Indicate the test(s)/procedure(s) which may be denied within the relevant reason column
- 4. Include an estimated cost for the test(s)/procedure(s) subject to the ABN
- 5. Have 'Option 1', 'Option 2', or 'Option 3' designated by the beneficiary
- 6. Be signed **and** dated by the beneficiary or his/her representative **prior to** the service being rendered



| ____

0300D Rev. 06/20/2023

8710117999

___ |

©2023 Laboratory Corporation of America® Holdings. All rights reserved.

+